TPST

Tempest Therapeutics Inc

Add to Watchlist

Advanced Chart

6.435

+0.185(2.960%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.470

Open

6.180

VWAP

6.27

Vol

62.35K

Mkt Cap

25.25M

Low

6.110

Amount

391.05K

EV/EBITDA(TTM)

Total Shares

22.22M

7.21M

EV/OCF(TTM)

P/S(TTM)

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-2.450

-39.21%

-2.590

-51.41%

-2.655

-51.37%

Estimates Revision

The market is revising No Change the revenue expectations for Tempest Therapeutics, Inc. (TPST) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -17.07%.

EPS Estimates for FY2025

Revise Downward

-24.54%

In Past 3 Month

Stock Price

Go Down

-17.07%

In Past 3 Month

2 Analyst Rating

39.86% Upside

Wall Street analysts forecast TPST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TPST is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

39.86% Upside

Current: 6.435

Low

9.00

Averages

9.00

High

9.00

39.86% Upside

Current: 6.435

Low

9.00

Averages

9.00

High

9.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Hold

Downgrades

$16

2025-04-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-04-10

Downgrades

Strong Buy

Hold

Reason

Scotiabank

George Farmer

Buy

Hold

Downgrades

$91 → $9

2025-04-10

Reason

Scotiabank

George Farmer

Price Target

$91 → $9

2025-04-10

Downgrades

Buy

Hold

Reason

Scotiabank downgraded Tempest Therapeutics to Sector Perform from Outperform.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$47 → $16

2025-03-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$47 → $16

2025-03-28

Maintains

Strong Buy

Reason

Scotiabank

George Farmer

Buy

Maintains

$13 → $7

2025-03-28

Reason

Scotiabank

George Farmer

Price Target

$13 → $7

2025-03-28

Maintains

Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$47

2024-11-13

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$47

2024-11-13

Reiterates

Strong Buy

Reason

Piper Sandler

Edward Tenthoff

Buy

Maintains

$8 → $5

2024-11-13

Reason

Piper Sandler

Edward Tenthoff

Price Target

$8 → $5

2024-11-13

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tempest Therapeutics Inc (TPST.O) is -0.61, compared to its 5-year average forward P/E of -1.32. For a more detailed relative valuation and DCF analysis to assess Tempest Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.32

Current PE

-0.61

Overvalued PE

-0.36

Undervalued PE

-2.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.70

Current EV/EBITDA

-0.33

Overvalued EV/EBITDA

0.58

Undervalued EV/EBITDA

-1.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00